Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy

被引：4
|
作者：
Li, Zihai [1 ,2 ]
Azar, Joseph H. [1 ,2 ]
Rubinstein, Mark P. [1 ,2 ]
机构：
[1] Ohio State Univ, Div Med Oncol, Dept Internal Med, Columbus, OH USA
[2] Ohio State Univ, James Comprehens Canc Ctr, Plotonia Inst Immunooncol, 460 W 12th Ave,BRT 510,Biomed Res Tower, Columbus, OH 43210 USA
来源：
CANCER DISCOVERY | 2022年 / 12卷 / 05期
关键词：
D O I：
10.1158/2159-8290.CD-22-0219
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dose-limiting toxicities are thought to temper the efficacy of single-agent 4-1BB agonists. To overcome this hurdle, in this issue of Cancer Discovery, Muik and colleagues report preclinical and clinical studies describing a first-in-class bispecific fusion protein targeting 4-1BB and PD-L1.
引用
收藏
页码：1184 / 1186
页数：3
相关论文
共 50 条
  • [31] Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
    Wang, Yichen
    Zhang, Xuyao
    Xu, Caili
    Nan, Yanyang
    Fan, Jiajun
    Zeng, Xian
    Kwon, Byoung S.
    Ju, Dianwen
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] Immunotherapy Targeting 4-1BB and Its Ligand
    Dass S. Vinay
    Byoung S. Kwon
    International Journal of Hematology, 2006, 83 : 23 - 28
  • [33] Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
    Hangiu, Oana
    Navarro, Rocio
    Frago, Susana
    Rubio-Perez, Laura
    Tapia-Galisteo, Antonio
    Diez-Alonso, Laura
    Gomez-Rosel, Marina
    Silva-Pilipich, Noelia
    Vanrell, Lucia
    Smerdou, Cristian
    Howard, Kenneth A.
    Sanz, Laura
    alvarez-Vallina, Luis
    Compte, Marta
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [34] Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
    Wu, Bogang
    Sun, Xiujie
    Gupta, Harshita B.
    Yuan, Bin
    Li, Jingwei
    Ge, Fei
    Chiang, Huai-Chin
    Zhang, Xiaowen
    Zhang, Chi
    Zhang, Deyi
    Yang, Jing
    Hu, Yanfen
    Curiel, Tyler J.
    Li, Rong
    ONCOIMMUNOLOGY, 2018, 7 (11):
  • [35] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Annika De Sousa Linhares
    Claire Battin
    Sabrina Jutz
    Judith Leitner
    Christine Hafner
    Joshua Tobias
    Ursula Wiedermann
    Michael Kundi
    Gerhard J. Zlabinger
    Katharina Grabmeier-Pfistershammer
    Peter Steinberger
    Scientific Reports, 9
  • [36] Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
    Linhares, Annika De Sousa
    Battin, Claire
    Jutz, Sabrina
    Leitner, Judith
    Hafner, Christine
    Tobias, Joshua
    Wiedermann, Ursula
    Kundi, Michael
    Zlabinger, Gerhard J.
    Grabmeier-Pfistershammer, Katharina
    Steinberger, Peter
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [37] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] PD-L1/PD-1 blockade in breast cancer: The immunotherapy era
    Li, Chia-Jung
    Lin, Li-Te
    Hou, Ming-Feng
    Chu, Pei-Yi
    ONCOLOGY REPORTS, 2021, 45 (01) : 5 - 12
  • [39] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
  • [40] Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
    Bertucci, Francois
    Goncalves, Anthony
    CURRENT ONCOLOGY REPORTS, 2017, 19 (10)
12345